European Organisation for Research and Treatment of Cancer

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 07 Jan 2021
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

37,500€

Financial year: Jan 2019 - Dec 2019

Lobbyists (Full time equivalent)

0.75 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

8

Lobbying Costs over the years

  • Info

    European Organisation for Research and Treatment of Cancer   (EORTC)

    EU Transparency Register

    70539554035-46 First registered on 20 Aug 2010

    Goals / Remit

    The European Organisation for Research and Treatment of Cancer (EORTC) is the largest independent cancer clinical research organization. The EORTC has delivered investigator driven, changing practice clinical trials since 1962. Its mission is to improve survival and quality of life of cancer patients. The EORTC is a not-for-profit independent organisation performing multidisciplinary clinical research activities across tumor types. EORTC’s activities involve on a voluntary basis more than 5300 medical doctors and scientists from 930 university hospitals in 36 countries. EORTC clinical trials are involving several thousands of patients on a yearly basis.

    Main EU files targeted

    - Regulation on clinical trials on medicinal products for human use.
    -Regulation on Health Technology Assessment.
    -Early access to medicines: PRIME, accelerated assessment, conditional market authorization.
    - Good Clinical Practice implementation.
    - General Data Protection Regulation.
    - Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices.
    - Euratom and radioprotection.
    - EU Beating Cancer plan.
    - EU Cancer Mission.
    - EU Roadmap for a pharmaceutical strategy for Europe.
    - Pharmaceutical strategy for Europe
    - EU Partnership for Health Innovation.

    Address

    Head Office
    avenue Mounier, 83
    Brussels 1200
    BELGIUM
  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    25%3

    Lobbyists (Full time equivalent)

    0.75

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    III - Non-governmental organisations

    Subcategory

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    European CanCer Organisation
    European Forum for Good Clinical Practice
    European Alliance for Personnalised Medicine
    European Association for NeuroOncology
    European Association of Urology
    European School of Oncology
    European Association of Urology
    American Association for Cancer Research
    European Society for Therapeutic Radiology and Oncology
    European Society for Medical Oncology
    American Society for Therapeutic Radiology and Oncology
    International Society of Geriatric Oncology
    International Society of Pediatric Oncology
    International Union Against Cancer
    International Network for Cancer Research and Treatment
    Organisation of European Cancer Institutes
    European Oncology Nursing Society
    European Society of Pathology
    European Society of Radiology

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2019 - Dec 2019

    Lobbying costs for closed financial year

    37,500€

    EU grant income for closed financial year

    326,000 € (Source: FP7,H2020, IMI)

    Other financial info

    The EORTC Cancer Research Fund (ECRF) is an independent non-profit association founded in 1976 under the honorary presidency of His Royal Highness Prince Philip, the Duke of Edinburgh. ECRF’s objective is to promote, encourage and support research on the treatment of cancer. To fulfil this, it engages in financing studies and research performed by the international non-profit organisation, EORTC.
    Funds come from grants and donations from institutional, corporate partnerships, private and public foundations, individual private donors, legacies and organisations’ in financial or in-kind donations to EORTC’s activities.
    Every single donation goes in full to specific EORTC projects chosen either by the donor or in the case of an unrestricted gift, by the EORTC to cancer research that lacks funding. In both cases, donors are able to follow and be part of EORTC’s journey in increasing survival and quality of life for all cancer patients.

    In addition, grants for EORTC research projects are received from the European Commission Research Framework Programmes FP7 and H2020.

    Clinical studies evaluating new drugs for potential registration or testing innovative therapeutic agents, including some educational projects, are conducted in cooperation with pharmaceutical industry partners in strict compliance with EORTC criteria for independence. Pharmaceutical industry financial support is also provided in the form of “unrestricted grants” for EORTC conferences.

    The finances of the EORTC includes all accounts from the EORTC Headquarters as well as all EORTC Groups. These accounts are consolidated as required under Belgian Law. The EORTC accounts are audited by Ernst & Young.

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    Cancer

    Communication activities

    Participation in workshops and conference involving EU institutions officials. Position statement in collaboration with stakeholders groups such European Cancer Organisation, European Alliance for Personalised Medicine, BioMedAlliance, Rare Cancers Europe, EFGCP, European Data in Health Research Alliance, , European Federation of Pharmaceutical Industries, FIPRA.

    EORTC is represented in the following working groups: Commission Expert Group on Clinical Trials, Commission HTA stakeholders pool, EMA CTIS new delivery model, EMA EV- Expert Working Group.

    Other activities

    - International investigator-driven clinical trials
    - Funding independent clinical research.
    - Human biological material for use in research
    - Secondary use of clinical data.
    - Precision Medicine
    - Real world data
    - Treatment optimization.
    - Access to treatment, quality of life.
    - Evidence generation for clinical decision.

    Keywords: Health, cancer, clinical and translational research, complex clinical trial, study sponsorship, medicine, drugs, surgery, radiotherapy, chemotherapy, imaging, laboratory, patient, pharmacovigilance, quality insurance, biostatistics, biobank, regulatory, quality of life, funding, sequencing, molecular screening platform.

  • Meetings

    Meetings

    8 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard